Just watched SI presentation at the Share Cafe Webinar. My key takeaways:
aGvHD:
* Coming quarter refiling
* Second half of year potential approval
* Small sales force as 50% of transplant centres in US
* Substantial reimbursement revenues (launch towards end of year)
* Japan seeing 30 - 40% adoption in market after 3 years
* Potency assay to predict clinical survival - new data shows this
* Very confident - resubmit data short order - review process 2 to 6 months
* Reiterated 9:1 ODAC vote - extra data requested around potency assays
IBD
* Current drugs on market cost about $60,000/year
* Update next couple of months further results
* Initial results outstanding
CLBP
* Most valuable opportunity - multi billion projected annual sales opportunity
* Second half of year to start CLBP trial
Interestingly didn't expand of CHF - intriguing - make of it what you wish. My thoughts probably because in discussions with FDA.
Mentioned extremely happy to have Dr Krause on board - asset for navigating first and subsequent products.
SI looks confident.
Good luck all!
Just watched SI presentation at the Share Cafe Webinar. My key...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |